rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ETON
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Explosive Growth Ignites This Biotech. But There's A Catch.

      Robust growth fuels Eton Pharmaceuticals, but the biotech faces key test.

      12h agoInvestor's Business DailyETON
      Eton Pharmaceuticals at Jefferies Global Healthcare Conference: growth quickens
      Nov 16Investing.comETONJEF
      Eton Pharmaceuticals: The Commercial Model Is Finally Scaling (NASDAQ:ETON)
      Nov 16Seeking AlphaETON
      Eton Pharmaceuticals CCO sells $235,937 in stock after option exercise
      Nov 12Investing.comETON
      Witnessing An Insider Decision, CHARLES CASAMENTO Exercises Options Valued At $4.99M At Eton Pharmaceutic
      Nov 11BenzingaETON
      Eton Pharmaceuticals (ETON) Unveils ET 900 And Shares Early ET 700 Clinical Data

      Eton Pharmaceuticals (NasdaqGM:ETON) announced a new ET-900 development program for infantile and epileptic spasms on 9 November 2026. Management said ET-900 is supported by preclinical evidence and external partnerships focused on epilepsy treatment research. The company released preliminary clinical results for its ET-700 formulation in Wilson disease, highlighting early patient data from an ongoing study. The ET-900 launch and first ET-700 readout only tell part of Eton's wider R&D story...

      Nov 11Yahoo FinanceETON
      Is Eton Pharmaceuticals (ETON) Still Below Fair Value As Earnings And Guidance Impress?
      Nov 11Yahoo FinanceETON
      Eton Pharmaceuticals stock hits all-time high at 66.54 USD
      Nov 10Investing.comETON
      Why Eton Pharmaceuticals Stock Is Up 19.7% And What's Next

      Eton Pharmaceuticals reported third quarter 2026 revenue of US$57.93 million and net income of US$35.25 million, reversing a loss from a year earlier and delivering US$1.06 in diluted earnings per share from continuing operations. The business lifted full year 2026 revenue guidance from more than US$145 million to more than US$175 million, indicating management confidence in demand for its branded rare disease portfolio and expanding pipeline. We will now see how Eton Pharmaceuticals’ sharp...

      Nov 7Yahoo FinanceETON
      Eton stock jumps on Q3 beat and guidance hike (ETON:NASDAQ)

      Eton Pharmaceuticals (ETON) stock surged after strong Q3 earnings, 158% revenue growth, and a raised outlook. Read more here.

      Nov 6Seeking AlphaETON
      Eton Pharmaceuticals Inc (ETON) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...
      Nov 6Yahoo FinanceETON
      Eton Pharmaceuticals Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceETON
      Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates
      Nov 6Yahoo FinanceETON
      Eton Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 5BenzingaETON
      Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
      Nov 5Yahoo FinanceETON
      Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
      Nov 5Yahoo FinanceETON
      Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
      Nov 4Yahoo FinanceETONJEF
      Earnings To Watch: Eton Pharmaceuticals Inc (ETON) Q3 2026 -- GF Value Sees 16% Downside
      Nov 4Yahoo FinanceETON
      ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
      Nov 2Yahoo FinanceETON
      Eton Pharmaceuticals submits IND for epileptic spasms trial
      Nov 2Investing.comETON
      Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

      DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET. Participant Call Link: Click HereWebcast:Click Here In addition to

      Oct 29Yahoo FinanceETON
      Eton Pharmaceuticals Has Stronger Earnings And Little Valuation Cushion (NASDAQ:ETON)
      Oct 23Seeking AlphaETON
      Eton Pharmaceuticals (ETON) Stock Still Looks Rich Despite Its New Seizure Drug License
      Oct 22Yahoo FinanceETON
      Weekly Note: Eton Pharmaceuticals, A Rare-Disease Compounder Priced For Its Weakest Year (NASDAQ:ETON)

      RARE, BHVN, DYN, UNCY, KURA, QURE, PHVS, SVRA, MESO, GRCE_______________________________________________Initiating coverage at BUY | 12-month price target...

      Oct 18Seeking AlphaETON
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Si-Bone Inc (SIBN-Q) from The Globe and Mail including charting and trades.

      Oct 16The Globe and MailETONSIBN
      Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug - Aquestive Therapeutic

      Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.

      Oct 14BenzingaAQSTETON
      Aquestive rises on licensing deal with Eton for antiseizure therapy
      Oct 14Seeking AlphaAQSTETON
      Eton Pharmaceuticals CBO David Krempa sells $229k in stock
      Oct 11Investing.comETON
      ETON Stock Surges 108% in Six Months: Here's What You Need to Know
      Oct 7Yahoo FinanceETON
      Eton Pharmaceuticals Relaunches IMPAVIDO for Rare Leishmaniasis Treatment

      Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailETON
      Eton Pharmaceuticals launches IMPAVIDO for leishmaniasis
      Sep 28Investing.comETON
      PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M
      Sep 1BenzingaETON
      Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)

      During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]

      Aug 28Yahoo FinanceETON
      Eton Pharmaceuticals Insider Sold Shares Worth $2,953,572, According to a Recent SEC Filing
      Aug 28Yahoo FinanceETON
      Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

      DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your

      Aug 27Yahoo FinanceETON
      Insider Unloading: David Krempa Sells Options, Realizes $1.43M
      Aug 25BenzingaETON
      Eton Pharmaceuticals stock hits all-time high at 64.29 USD
      Aug 24Investing.comETON
      Eton Pharmaceuticals Insider Sold Shares Worth $1,626,750, According to a Recent SEC Filing

      David Krempa, Chief Business Officer, on August 24, 2026, sold 25,000 shares in Eton Pharmaceuticals

      Aug 24Yahoo FinanceETON
      SEAN BRYNJELSEN Executes Sell Order: Offloads $6.09M In Eton Pharmaceuticals Stock
      Aug 21BenzingaETON
      Three Biotech Stocks Stick Out With Their Stellar Charts

      These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

      Aug 21Investor's Business DailyETONKNSATVTX

      This is the newest page. Registered accounts read further back.